Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Glass

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
Leukemia|March 28, 2024
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trialMichael Oertel, Marita Ziepert, Fabian Frontzek, et al.
Annals of Hematology|November 26, 2020
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group)Florian Zettl, Marita Ziepert, Bettina Altmann, et al.
British Journal of Haematology|December 7, 2018
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trialBirte Friedrichs, Maike Nickelsen, Marita Ziepert, et al.
The Lancet. Oncology|May 16, 2014
Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trialBertram Glass, Justin Hasenkamp, Gerald Wulf, et al.
Bone Marrow Transplantation|October 31, 2021
Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMTOlaf Penack, Christophe Peczynski, Mohamad Mohty, et al.
Blood|February 26, 2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLMichael Pfreundschuh, Lorenz Trümper, Marita Kloess, et al.
Blood|September 19, 2013
High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysisDaniel Fürst, Carlheinz Müller, Vladan Vucinic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab eraChristian Gisselbrecht, Bertram Glass, Nicolas Mounier, et al.
Blood Advances|June 13, 2022
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST studyNico Gagelmann, Gerald Georg Wulf, Johannes Duell, et al.
Journal of Cancer Research and Clinical Oncology|April 9, 2026
High serum ferritin is associated with genetic instability in myelodysplastic neoplasmsChristina Ganster, Hannes Treiber, Gina Westhofen, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Leukemia|March 28, 2024
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trialMichael Oertel, Marita Ziepert, Fabian Frontzek, et al.
Annals of Hematology|November 26, 2020
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group)Florian Zettl, Marita Ziepert, Bettina Altmann, et al.
British Journal of Haematology|December 7, 2018
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trialBirte Friedrichs, Maike Nickelsen, Marita Ziepert, et al.
The Lancet. Oncology|May 16, 2014
Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trialBertram Glass, Justin Hasenkamp, Gerald Wulf, et al.
Bone Marrow Transplantation|October 31, 2021
Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMTOlaf Penack, Christophe Peczynski, Mohamad Mohty, et al.
Blood|February 26, 2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLMichael Pfreundschuh, Lorenz Trümper, Marita Kloess, et al.
Blood|September 19, 2013
High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysisDaniel Fürst, Carlheinz Müller, Vladan Vucinic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab eraChristian Gisselbrecht, Bertram Glass, Nicolas Mounier, et al.
Blood Advances|June 13, 2022
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST studyNico Gagelmann, Gerald Georg Wulf, Johannes Duell, et al.
Journal of Cancer Research and Clinical Oncology|April 9, 2026
High serum ferritin is associated with genetic instability in myelodysplastic neoplasmsChristina Ganster, Hannes Treiber, Gina Westhofen, et al.
Pageof 10